NCT06777316
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06777316
Title A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Cogent Biosciences, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Stanford Cancer Institute Palo Alto California 94305 United States Details
Mayo Clinic Jacksonville Jacksonville Florida 32224 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
University of Chicago Medicine Comprehensive Cancer Center Chicago Illinois 60637 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Mayo Clinic Rochester Rochester Minnesota 55905 United States Details
The Christ Hospital Cincinnati Ohio 45219 United States Details
Taussig Cancer Center - Cleveland Clinic Cleveland Ohio 44195 United States Details
Fox Chase cancer Center Philadelphia Pennsylvania 19111 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Huntsman Cancer Institute - University of Utah Salt Lake City Utah 84112 United States Details
Princess Margaret Cancer Centre - UHN Toronto Ontario M5G 2C4 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field